Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective

卷:12

Review

关键词: INHIBITOR TRAMETINIB GSK1120212;    RAS-EFFECTOR INTERACTIONS;    CELL-BASED IMMUNOTHERAPY;    ACQUIRED-RESISTANCE;    COLON-CANCER;    GENERAL STRATEGY;    ONCOGENIC KRAS;    COMBINATION;    ANTIBODIES;    DELIVERY;   

DOI  :  10.3390/cells12040631

来源: SCIE

【 摘 要 】

This review summarizes recent development in synthetic drugs and biologics targeting intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current perspective and potential leads for the field. Compared to biologics, small molecule inhibitors (SMIs) readily penetrate cells, thus being able to target intracellular proteins. However, SMIs frequently suffer from pleiotropic effects, off-target cytotoxicity and invariably elicit resistance. In contrast, biologics are much larger molecules limited by cellular entry, but if this is surmounted, they may have more specific effects and less therapy-induced resistance. Exciting breakthroughs in the past two years include engineering of non-covalent KRAS G12D-specific inhibitor, probody bispecific antibodies, drug-peptide conjugate as MHC-restricted neoantigen to prompt immune response by T-cells, and success in the adoptive cell therapy front in both breast and pancreatic cancers.